Gsk Plc Quick Ratio (GSK) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gsk Plc  (NYSE: GSK)

Gsk Plc's Quick Ratio

GSK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.11 below Gsk Plc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 489 other companies have achieved higher Quick Ratio than Gsk Plc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 4439 to 4707.

Explain Quick Ratio?
How much Cash & cash equivalents GSK´s has?
What are GSK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GSK/financial-strength
https://api.csimarket.com/api/v1/companies/GSK/fundamentals
https://api.csimarket.com/api/v1/companies/GSK/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
GSK Quick Ratio (Dec 31 2025)
Q4		 0
Q3 		0
Q2 		0
Q1 		(Dec 31 2024)
Q4
Y / Y Current Liabilities Change 7.09 %
Y / Y Cash & cash equivalent Change -8.6 %
Quick Ratio MRQ 0.11
GSK's Total Ranking # 4707
Seq. Current Liabilities Change 0 %
Seq. Cash & cash equivalent Change -6.85 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 490
Healthcare Sector # 971
Overall Market # 4572


Quick Ratio Statistics
High Average Low
0.18 0.12 0.09
(Dec 31 2016)   (Dec 31 2023)




Financial Statements
Gsk Plc's Current Liabilities $ 41,130 Millions Visit GSK's Balance sheet
Gsk Plc's Cash & cash equivalent $ 4,429 Millions Visit GSK's Balance sheet
Source of GSK's Sales Visit GSK's Sales by Geography


Cumulative Gsk Plc's Quick Ratio

GSK's Quick Ratio for the trailling 12 Months

GSK Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months 		0
12 Months 		0
12 Months 		(Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 7.09 %
Y / Y Cash & cash equivalent TTM Growth -3.55 %
Quick Ratio TTM 0.11
Total Ranking TTM # 4734
Seq. Current Liabilities TTM Growth 1.68 %
Seq. Cash & cash equivalent TTM Growth -2.18 %

Quick ratio ranking by company, industry and sector >> Back to GSK Financial Strength Comparisons >> Go to Compare GSK Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $41,130.34 millions, cumulative Quick Ratio decreased to 0.11 below the Gsk Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 490 other companies have achieved higher Quick Ratio than Gsk Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4734.

Explain Quick Ratio?
How much Cash & cash equivalents GSK´s has?
What are GSK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 491
Healthcare Sector # 1007
Within the Market # 4734


trailing twelve months Quick Ratio Statistics
High Average Low
0.28 0.18 0.14
(Dec 31 2020)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Sanofi  0.29 $ 9,515.549  Millions$ 32,510.093  Millions
Nrx Pharmaceuticals Inc   0.27 $ 7.797  Millions$ 28.578  Millions
Telix Pharmaceuticals Ltd  0.27 $ 147.909  Millions$ 542.825  Millions
Biolinerx Ltd   0.27 $ 3.250  Millions$ 12.123  Millions
Summit Therapeutics Inc   0.27 $ 16.538  Millions$ 61.966  Millions
Phibro Animal Health Corporation  0.26 $ 74.508  Millions$ 282.370  Millions
Cumberland Pharmaceuticals Inc   0.26 $ 11.445  Millions$ 44.519  Millions
Teva Pharmaceutical Industries Limited  0.25 $ 3,556.000  Millions$ 14,068.000  Millions
Organon and Co   0.24 $ 574.000  Millions$ 2,390.000  Millions
Novo Nordisk A  0.24 $ 4,920.176  Millions$ 20,636.707  Millions
Hcw Biologics Inc   0.23 $ 1.953  Millions$ 8.625  Millions
Galapagos Nv  0.23 $ 40.000  Millions$ 177.333  Millions
International Stem Cell Corporation  0.22 $ 0.993  Millions$ 4.579  Millions
Intercure Ltd   0.22 $ 46.466  Millions$ 214.365  Millions
Earth Science Tech Inc   0.21 $ 0.473  Millions$ 2.260  Millions
Redhill Biopharma Ltd   0.21 $ 3.971  Millions$ 19.221  Millions
Polomar Health Services, Inc.  0.21 $ 0.141  Millions$ 0.687  Millions
Citius Pharmaceuticals Inc   0.20 $ 7.721  Millions$ 38.207  Millions
Quantum Cyber N v   0.20 $ 0.832  Millions$ 4.240  Millions
Adlai Nortye Ltd  0.19 $ 8.056  Millions$ 41.628  Millions
Viatris Inc   0.19 $ 1,388.100  Millions$ 7,420.600  Millions
Igc Pharma Inc   0.18 $ 0.405  Millions$ 2.257  Millions
Citius Oncology Inc  0.16 $ 7.295  Millions$ 44.710  Millions
Bioxytran Inc   0.16 $ 0.510  Millions$ 3.147  Millions
Neurosense Therapeutics Ltd  0.16 $ 0.213  Millions$ 1.358  Millions
Propanc Biopharma Inc   0.15 $ 0.561  Millions$ 3.624  Millions
Pmgc Holdings Inc   0.15 $ 0.572  Millions$ 3.942  Millions
Casi Pharmaceuticals inc   0.14 $ 7.348  Millions$ 51.425  Millions
Aspire Biopharma Holdings Inc   0.13 $ 1.004  Millions$ 7.593  Millions
Astrazeneca Plc  0.13 $ 6,869.000  Millions$ 52,465.000  Millions

Date modified: 2026-11-10T13:12:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.